Serum Calprotectin Is a Potential Marker in Patients with Asthma
10.3346/jkms.2020.35.e362
- Author:
Yun-Gi LEE
1
;
Ji su HONG
;
Pureun-Haneul LEE
;
June hyuk LEE
;
Sung-Woo PARK
;
Do Jin KIM
;
An-Soo JANG
Author Information
1. Division of Allergy and Respiratory Medicine, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
- Publication Type:Original Article
- From:Journal of Korean Medical Science
2020;35(43):e362-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Calprotectin is the major cytosolic protein in neutrophil granulocytes.Although asthma is known to cause eosinophilic inflammation, some patients with asthma have non-eosinophilic inflammation, which is characterized by local neutrophilic inflammation. The aim of this study was to assess calprotectin expression levels in a mouse model of asthma, and to observe the relationship of serum calprotectin level and clinical variables in patients with asthma.
Methods:Mice were sensitized and challenged with 10 μg and 20 μg of Aspergillus fumigatus, respectively; mice treated with saline were used as a control. The levels of calprotectin were determined using enzyme-linked immunosorbent assay, immunoblotting, and immunohistochemical analysis. The serum levels of calprotectin were also assessed in patients with asthma. The relationship between calprotectin and clinicopathological characteristics was determined.
Results:Calprotectin, S100A8, and S100A9 expression was elevated in the mouse lungs, Calprotectin levels were higher in the serum of patients with asthma (n = 33) compared with those of healthy individuals (n = 28). Calprotectin levels correlated with forced expiratory volume in one second/forced vital capacity (r = −0.215, P = 0.043), smoke amount (r = 0.413, P = 0.017), body mass index (r = −0.445,P= 0.000), and blood neutrophil percentage (r = 0.300, P = 0.004) in patients with asthma.
Conclusion:Our data suggest that calprotectin could potentially be used as a biomarker for asthma.
